NDAVAGINALINSERT
Approved
May 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
IMVEXXY (estradiol) by Pfizer is estrogen receptor agonists [moa]. Approved for menopause, contraception, vaginal atrophy. First approved in 2018.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IMVEXXY is a vaginal insert formulation of estradiol approved by the FDA in May 2018 for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. It works as an estrogen receptor agonist, delivering localized hormone therapy directly to vaginal tissues. The product represents Pfizer's innovation in the vaginal estrogen space, offering an alternative delivery method to existing transdermal patches and creams in the menopausal symptom management market.
$0.0BPart D
7.7 years to LOEMechanism of Action
Estrogen Receptor Agonists
Pharmacologic Class:
Estrogen
Indications (3)
Worked on IMVEXXY at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.